This review provides a comprehensive overview of the current knowledge of the pathophysiology and up-to-date therapeutic options targeting pathogenic cascades of the cytokine IL-12/23 and the downstream JAK/STAT pathway for IBD treatment. The gene discussed is SOAT1; the disease is inflammatory bowel disease.